Multiple trials (e.g., DAPA-HF, EMPEROR-Reduced, DECLARE-TIMI 58) have shown SGLT2 inhibitors’ effects in HFrEF, reducing HF hospitalizations by 30–40% and cardiovascular death by 20% [16,17,18]. The gene discussed is SLC5A2; the disease is hydrops fetalis.